Author

A. Pinto

Observed name: A Pinto

Institution: Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Observed institutions: Federico II University Hospital, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Naples Federico II

OpenAlex ID: A5079718348

Preliminary evaluation of radioimmunotherapy with Tenarad, a I-131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin lymphoma.

2011 · L. Aloj, L. D'Ambrosio, et al. · Journal of Clinical Oncology · 4

A First‐in‐human Trial of the Novel Multi‐action Therapy Tinostamustine (edo‐s101) in Patients With Relapsed/refractory (r/r) Hodgkin Lymphoma (hl)

2019 · A. Pinto, R. De Filippi, et al. · Hematological Oncology · 2

833 | Pro‐mind: Prospective Real‐world Study of Tafasitamab Plus Lenalidomide in Relapsed or Refractory Diffuse Large B‐cell Lymphoma in Italy—an Ongoing Trial

2025 · P. L. Zinzani, G. Gini, et al. · Hematological Oncology · 1

223 | PROGNOSTIC ROLE OF INTERIM ΔSUVmax IN FOLLICULAR LYMPHOMA

2025 · R. Durmo, S. Chauvie, et al. · Hematological Oncology

349 | Pembrolizumab or Nivolumab Combined With Brentuximab‐vedotin in Patients With Relapsed/refractory Primary Mediastinal B‐cell Lymphoma: an Italian Real‐life Study

2025 · A. Broccoli, L. Argnani, et al. · Hematological Oncology

Real Life Experience With Brentuximab Vedotin: the Italian Study on 234 Relapsed/refractory H Odgkin's Lymphoma

2017 · C. Pellegrini, A. Pulsoni, et al. · Hematological Oncology

A255 2CdA and Rituximab Combination Treatment for Patients with Waldenström: Results of a Multicenter Study

2009 · D Laszlo, C Rabascio, et al. · Clinical Lymphoma & Myeloma

Works count: 7

Citation count: 7

H-index: 2

I10-index: